₹430.85
▼ -1.47 -0.34%
As of 29 Jul 2026 · delayed
BSE Listed · Pharmaceuticals
Biocon Ltd. (532523)
Volume: 1,01,057Avg Vol 1W: 3,10,231Avg Vol 1M: 24,21,77852W Range:₹331₹447
Key Ratios
Checked 3h agoMarket Cap₹69,837 Cr
Current Price₹430.85
Previous Close₹432.32
High / Low (52w)₹447 / ₹331
Volume1,01,057
Avg Vol (1W)3,10,231
Avg Vol (1M)24,21,778
Stock P/E545.38
Book Value₹209.94
Dividend Yield0.12%
ROE1.14%
ROA0.58%
Revenue (TTM)—
Revenue Growth3.43%
Profit Margin2.3%
Total Debt₹12,405 Cr
Shares Outstanding162 Cr
Face Value₹5
EPS (TTM)₹0.79
P/B2.05
Debt / Equity0.45
50 DMA₹423.16
200 DMA₹389.82
Day change-0.34%
Price Chart
₹430.85▲ 8.17% · 1Y
2025-07-292026-07-29
20-day avg volume: 26.5L shares
Pros
- Company is almost debt-free.
- Revenue grew 2756% YoY.
- Net profit is growing year over year.
Cons
- Stock trades at a high P/E of 545.
Quarterly Results
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3,433 Cr | ₹3,590 Cr | ₹3,821 Cr | ₹4,417 Cr | ₹3,942 Cr | ₹4,296 Cr | ₹4,173 Cr | ₹4,517 Cr |
| EBITDA | ₹1,350 Cr | ₹298 Cr | ₹361 Cr | ₹679 Cr | ₹374 Cr | ₹455 Cr | ₹436 Cr | ₹559 Cr |
| Net Profit | ₹660 Cr | ₹-16 Cr | ₹25 Cr | ₹345 Cr | ₹31 Cr | ₹85 Cr | ₹144 Cr | ₹126 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Dec 2024 | Mar 2025 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹563 Cr | ₹16,470 Cr | ₹644 Cr | ₹537 Cr | ₹583 Cr | ₹621 Cr | ₹17,270 Cr | ₹605 Cr |
| EBITDA | ₹62 Cr | ₹2,688 Cr | ₹92 Cr | ₹49 Cr | ₹153 Cr | ₹114 Cr | ₹1,841 Cr | ₹93 Cr |
| Net Profit | ₹584 Cr | ₹1,013 Cr | ₹21 Cr | ₹-8 Cr | ₹71 Cr | ₹-76 Cr | ₹386 Cr | ₹51 Cr |
| EPS | — | 8.46 | — | — | — | — | 2.82 | — |
Balance Sheet
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹12,192 Cr | ₹14,444 Cr | ₹18,522 Cr | ₹20,394 Cr | ₹52,043 Cr | ₹56,071 Cr | ₹58,797 Cr | ₹63,651 Cr |
| Total Liabilities | ₹5,486 Cr | ₹7,061 Cr | ₹10,015 Cr | ₹10,924 Cr | ₹29,554 Cr | ₹30,796 Cr | ₹31,085 Cr | ₹27,029 Cr |
| Equity | ₹6,707 Cr | ₹7,383 Cr | ₹8,508 Cr | ₹9,470 Cr | ₹22,489 Cr | ₹25,275 Cr | ₹27,713 Cr | ₹36,622 Cr |
| Total Debt | — | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating | ₹1,446 Cr | ₹1,627 Cr | ₹1,354 Cr | ₹1,439 Cr | ₹2,081 Cr | ₹3,246 Cr | ₹4,521 Cr | ₹2,237 Cr |
| Investing | ₹-714 Cr | ₹-1,559 Cr | ₹-3,625 Cr | ₹-1,699 Cr | ₹-14,282 Cr | ₹-1,004 Cr | ₹-234 Cr | ₹-2,082 Cr |
| Financing | ₹-242 Cr | ₹388 Cr | ₹2,564 Cr | ₹242 Cr | ₹13,049 Cr | ₹-2,333 Cr | ₹-1,854 Cr | ₹-924 Cr |
| Free Cash Flow | ₹1,446 Cr | ₹1,627 Cr | ₹1,354 Cr | ₹1,439 Cr | ₹2,081 Cr | ₹3,246 Cr | ₹4,521 Cr | ₹2,237 Cr |
Shareholding
Promoter 44.68% Institutions 31.53% Public 23.8%
Efficiency & Working Capital
ROCE6.9%
Interest Coverage1.8
Dividend Payout—
Debtor Days129 d
Inventory Days131 d
Payable Days146 d
Cash Conversion Cycle114 d
Working Capital Days260 d
Shareholding Details
As of 2026-06-30
Promoter44.7%
FII8.1%
DII23.4%
Institutions31.5%
Public23.8%
Promoter Pledge0%
No. of Shareholders3,92,833
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Jan 2026 | Jan 2026 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 60.6% | 60.6% | 60.6% | 60.6% | 60.6% | 54.5% | 54.5% | 54.5% | 44.9% | 44.9% | 44.9% | 44.7% |
| FIIs | 5.6% | 5.9% | 5.9% | 5.7% | 5.7% | 6% | 6.6% | 7.4% | 7.1% | 7.1% | 7.5% | 8.1% |
| DIIs | 13.7% | 14.3% | 14.4% | 15.4% | 15.7% | 22.8% | 22.1% | 21.7% | 24.2% | 24.2% | 24.1% | 23.4% |
| Public | 20.1% | 19.2% | 19% | 18.3% | 18% | 16.7% | 16.8% | 16.4% | 23.6% | 23.8% | 23.5% | 23.8% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 4,70,261 | 4,43,513 | 4,39,503 | 4,27,705 | 4,24,297 | 4,28,131 | 4,13,191 | 3,94,279 | 3,94,759 | 3,94,759 | 3,86,593 | 3,92,833 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202603 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Kiran Mazumdar Shaw | Shareholding of Promoter and Promoter Group | 29.7% | 48.46 Cr |
| Glentec International | Shareholding of Promoter and Promoter Group | 14.6% | 23.72 Cr |
| Magnum Hybrid Long Short Fund | Public Shareholding | 8.8% | 14.27 Cr |
| Mylan Inc. | Public Shareholding | 5.6% | 9.20 Cr |
| Life Insurance Corporation Of India | Public Shareholding | 3.7% | 6.08 Cr |
| Serum Institute Life Sciences Private Limited | Public Shareholding | 3.4% | 5.54 Cr |
| Isif Equity Ex-top 100 Long-short Fund | Public Shareholding | 1.5% | 2.37 Cr |
| Kotak Mahindra Trustee Co Ltd A/c Kotak Nifty Midc | Public Shareholding | 1.3% | 2.10 Cr |
| Activ Pine Llp | Public Shareholding | 1.1% | 1.77 Cr |
| Hdfc Life Insurance Company Limited | Public Shareholding | 1% | 1.65 Cr |
| Ravi Rasendra Mazumdar | Shareholding of Promoter and Promoter Group | 0.3% | 53,58,440 |
| Dev Mazumdar | Shareholding of Promoter and Promoter Group | 0.1% | 9,29,721 |
| Glenloch Properties Llp | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Mazumdar Shaw Medical Foundation | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Carica Investment | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Jeeves | Shareholding of Promoter and Promoter Group | 0% | 0 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Kiran Mazumdar Shaw | Chairman/ED & CEO | 2026 |
| Ravi Mazumdar | Non-Exec & Non-Independent Dir | 2026 |
| Eric Vivek Mazumdar | Non-Exec & Non-Independent Dir | 2026 |
| Naina Lal Kidwai | Lead Independent Director | 2026 |
| Rekha Mehrotra Menon | Independent Non Exe. Director | 2026 |
| NICHOLAS ROBERT HAGGAR | Independent Non Exe. Director | 2026 |
| Atul Dhawan | Independent Non Exe. Director | 2026 |
| Shreehas Pradeep Tambe | Managing Director & CEO | 2026 |
| RAJESH UMAKANT SHANOY | Company Sec. & Compli. Officer | 2026 |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| India | ₹890 Cr | 45.4% |
| Singapore | ₹153 Cr | 7.8% |
| Brazil | ₹148 Cr | 7.6% |
| Rest of the world | ₹769 Cr | 39.2% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2026 | ₹5 | 900 | 811 | 811 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| dividend | 2026-07-03 | ₹0.5 (10.0%) | Final |
| dividend | 2026-07-03 | ₹0.5 (10%) | Final |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2026 | 14,354 | 0 | 0 | 41 | 6 | 14,400 |
| 2026 | 13,165 | 0 | 0 | 0 | 0 | 13,165 |
| 2026 | 465 | 0 | 0 | 41 | 6 | 512 |
Insider / Designated-Person Trades
30 recent disclosure(s)
SIVANANDAM K RevisedPledge · 7,328
NEHAL VORAPledge · 61,827
SIVANANDAM KPledge · 7,328
KIRAN KUMAR GANDHIRAJANDisposal · 19,998
AKHILESH NANDDisposal · 11,000
RAHUL AGRAWALAcquisition · 2,000
Substantial Acquisitions (SAST)
2 disclosure(s)
Market16/01/2026 · 3,34,70,117
Market11/11/2025 · 3,70,150
Company Information
🌐 www.biocon.com ↗
📍 20th KM Hosur Road Hebbagodi, Electronic City P O, Bangalore, Karnataka, 560100
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search